Mobile

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this stu...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004024-54

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naïve-adult subjects as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 48

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection

Liens